MINI FUTURE LONG - ELI LILLY & CO | Real-time Bid/Ask 09:51:05 12/07/2024 BST | ||
| 56.92 EUR / 56.97 EUR | -1.65% |
|
| Current month | +4.42% | ||
| 1 month | +7.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 11/07/24 | 57.9 | +0.54% |
| 10/07/24 | 57.59 | +1.16% |
| 09/07/24 | 56.93 | +2.58% |
| 08/07/24 | 55.5 | +3.47% |
| 05/07/24 | 53.64 | -0.91% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 11:38 am
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MD5LS3 |
| ISIN | DE000MD5LS38 |
| Date issued | 27/06/2022 |
| Strike | 316.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.03 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 57.9 € |
|---|---|
| Lowest since issue | 2.53 € |
| Spread | 0.05 € |
| Spread % | 0.09% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Certificates
- Certificat
